We're pleased to be included in this Nature Biotechnology editorial about the need for better, longer synthetic DNA. Our tech has improved a lot since the original publication in 2018, and we can’t wait to see what our customers accomplish next. 🧪 www.nature.com/articles/s41... #synbio

📣 We’re proud to partner with Waterfall Scientific on ESCALATOR, an ARPA-H GIVE project advancing on-demand production of high-purity #mRNA therapeutics and #vaccines. Read more: www.businesswire.com/news/home/20...

💡 #DYK: We went from 600 bp → 50 kb in just 15 months The bigger story? Expanding what researchers can design, build, and explore. More design freedom. More possibilities. More room to push science forward. What will you build with 50 kb? hubs.li/Q04t4hp20

Today’s AI models can predict expression, optimize sequences, design CRISPR guides, and generate entirely new proteins and DNA sequences. The challenge is turning those digital designs into physical constructs that can actually be tested. Let's dive in! 🧬 hubs.li/Q04sPdvK0 🧪

How AI Is Changing DNA and Gene Design | Ansa Biotechnologies

Discover how AI is transforming DNA and gene design, from expression prediction to generative sequence creation, and why synthesis is what closes the loop.

hubs.li

🧬 AI can now design mRNA sequences no one would've thought to try. The catch? Some of them are nearly impossible to actually build. Our CSO & Co-founder, Daniel Lin-Arlow, spoke with Biocompare about this gap between AI-designed and AI-buildable. 👉 hubs.li/Q04r_45V0

Next-Generation Vaccines Build On mRNA’s Breakthrough

New tools are extending the gains mRNA vaccines made during COVID-19

hubs.li

Synthetic DNA companies don't usually ask to be regulated. We're doing it anyway. In a new op-ed for The Scientist , our CEO Jason T. Gammack argues that the current #biosecurity screening honor system isn't enough. Read the full piece here: hubs.li/Q04r1-9G0

It’s Not Safe to Leave Biosecurity to the Honor System | The Scientist

Synthetic DNA providers are asking for enforceable biosecurity screening rules. Congress should give them some.

hubs.li

🔎 DNA synthesis biosecurity runs largely on the honor system today. As generative AI lowers the barrier to designing harmful biological agents, that's no longer good enough. Ansa's VP of Informatics, Scott Fay, shares his perspective on what's needed. hubs.li/Q04pvwxM0 #biosecurity #synbio

Better Biosecurity for DNA Synthesis in the AI Era | Scott Fay

AI is making it easier to design dangerous pathogens. That's real. But our biosecurity system for DNA synthesis needs stronger governance, standards, and incentives for compliance.

hubs.li

🧬 𝗬𝗼𝘂 𝗮𝘀𝗸𝗲𝗱, 𝘄𝗲 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱! By popular request, we're extending our iGEM Competition program submission window for 𝘁𝘄𝗼 𝗺𝗼𝗿𝗲 𝘄𝗲𝗲𝗸𝘀 — now closing 𝗝𝘂𝗹𝘆 𝟯𝟭𝘀𝘁. Don't miss this extended window — submit today! 👉 ansabio.com/igem

Ansa Biotechnologies@ansabio.bsky.social · 3mo ago

🧬 Calling all 2026 iGEM teams! We are excited to support this year's iGEM Competition by providing up to 20 kb of synthetic clonal DNA to 20 selected teams. Applications are open through June 30. 👉Apply: ansabio.com/igem/ #BIOsky #iGEM

𝗛𝗲𝗹𝗽𝗶𝗻𝗴 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗸𝗲𝗲𝗽 𝗽𝗮𝗰𝗲 𝘄𝗶𝘁𝗵 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Take a peek inside the partnership with @idtdna.bsky.social in this article by Christopher Vakulskas, who truly put us through our paces. bit.ly/3R1cECC

Helping synthesis keep pace with discovery: Inside the IDT-Ansa partnership

The pace of synthetic biology is accelerating—and with it, the complexity of the DNA constructs researchers are being asked to design, build, and validate. Longer constructs, difficult motifs, and inc...

bit.ly

32 Cas9 gRNAs cloned in a single reaction. And arrays that once took 3-4 months, delivered in <7 days. Thanks, Daniel, for sharing how Ansa helped transform your tomato transformation research! 🧬 Ready for your tools to move at the speed of your ideas? hubs.li/Q04nNQG20

🎥 NOW AVAILABLE: Our webinar, 'Codon Optimization Insn't Equal' is now available to watch on demand. Learn how AI-optimized antibody constructs consistently outperformed other approaches on transient expression titers in CHO cells in a benchmark study. hubs.li/Q04mbc6g0 #BioSKY #synbio 🧪🧬

"For the first time in my career, synthesis is no longer the bottleneck in my science." Thanks to Colin Harvey, Co-founder & VP of Early Discovery at Hexagon Bio for sharing his experience. We built Ansa differently, to serve scientists the constructs they need, on time. ansabio.com/guarantee/

We just extended direct synthesis of fragments to 900 bp including high GC content, repetitive regions, and strong secondary structures, delivered in as little as 4 days. One fragment. No workarounds. Shipping time guaranteed. 👉 ansabio.com/products/dna... 🧪 #BIOsky #synbio

🧬 Calling all 2026 iGEM teams! We are excited to support this year's iGEM Competition by providing up to 20 kb of synthetic clonal DNA to 20 selected teams. Applications are open through June 30. 👉Apply: ansabio.com/igem/ #BIOsky #iGEM

📣 WEBINAR ALERT: Join us to explore how gene design choices can impact antibody expression outcomes. 🗓️Thursday, June 11 ⏲️ 8am PT 🔹11 am ET 🔹3pm GMT Featuring Justin Byers and Daniel Lin-Arlow, this session will also include a live Q&A. 👉 hubs.li/Q04j2-J_0

Codon optimization is one of the most widely used (and misunderstood) tools in synthetic biology. And in many cases, the biggest limitation isn’t biology... it’s manufacturability. We dig into the issue on our blog. 🔗 hubs.li/Q04h8XcR0 #BIOsky 🧪

🧪From synthetic biologist to startup founder to leading the scientific vision of a company pushing the boundaries of what’s possible in DNA synthesis. The Scientist spotlights the journey, mindset and curiosity of our CSO and Co-Founder, Daniel Lin-Arlow Read the article here: hubs.li/Q04g_h8_0

Career Chat: A Synthetic Biologist-Turned-Startup Founder Leads the Company’s Scientific Vision | The Scientist

Daniel Lin-Arlow launched a company to tackle limitations in DNA synthesis. Today, he serves as the chief scientific officer at Ansa Biotechnologies.

hubs.li

🧬 How far can your DNA take you? 🧪 For most teams, the answer is still constrained by what can actually be built. At Ansa Biotechnologies, we’ve removed that limitation so you can design to the needs of biology, not the constraints of your typical DNA provider. 👉 Check us out: www.ansabio.com

“The constraints we've been taught to accept are not laws of nature—they're artifacts of legacy manufacturing.” Check out this perspective by Ansa CEO Jason T. Gammack ahead of #SynBioBeta. 👉 bit.ly/3Qxk2VJ

Jason Gammack: The Constraints Were Always Manufacturing Artifacts

In an exclusive conversation ahead of his appearance at SynBioBeta 2026 on May 4-7th in San Jose, Jason T. Gammack previewed his talk that reframes the synthetic biology bottleneck most researchers ha...

bit.ly

We can read DNA. We can design DNA. But building it? Still one of the biggest bottlenecks in biology. To mark #DNADay tomorrow, we're sharing a chat with Ansa CEO Jason T. Gammack about where the field is going: ansabio.com/resources/vi...

As we reflect on #sustainability in science this #EarthDay, there’s an uncomfortable question worth asking: Why does the foundation of synthetic biology still rely on processes that generate so much waste? We believe there's a better way. 🧪 Learn more: ansabio.com/technology/

After 20+ years in DNA synthesis, Ansa’s new COO Matthias Arenskötter shares why the field needs a new approach, and how long, reliable DNA unlocks real design freedom. 📖 www.linkedin.com/pulse/after-...

After Two Decades in the DNA Synthesis Space, I’m Joining a Startup That’s Changing the Whole Field

I’m really excited to be joining Ansa Biotechnologies as the company’s chief operating officer. In this role, I’ll be able to use my expertise in DNA and gene synthesis technology and operations to he...

linkedin.com

We’re excited to welcome Matthias Arenskötter as Ansa’s new COO. With 20+ years in DNA synthesis+ deep expertise in scaling advanced manufacturing, Matthias will lead global ops across manufacturing, supply chain & QA as we meet rising demand for long, complex DNA. 🔗 ansabio.com/news-events/...

#Biosecurity isn’t a ‘nice to have’ in DNA synthesis. It’s a core responsibility in our field. At Ansa, every DNA order is screened & verified before manufacturing begins, w/ automated sequence checks, expert review, and strong data security to protect sensitive designs. 👉 hubs.li/Q04869W-0

The biggest limitation in DNA synthesis isn’t cost. It’s: • Sequence rejection • Unpredictable timelines 🧪 Accessing complex DNA is only half the problem. Getting it when you expect it is what keeps science moving. 📑 Read the Tech Note here: hubs.li/Q047n2hW0 #BIOsky

Move beyond limitations! When complexity stops others, we keep going. We’ve partnered with @ansabio.bsky.social to provide you with long, complex clonal DNA up to 50 kb. Expect fast turnaround, dependable delivery, and sequence-perfect DNA, so your boldest ideas don’t have to wait: idtb.io/07t7jr

📣 Our team is excited to share that our synthetic DNA contributed to a new study in Nature led by @arcinstitute.org introducing the Evo 2 genomic foundation model. 📑 Read the paper: lnkd.in/gxJS8rSJ

Genome modelling and design across all domains of life with Evo 2 - Nature

Evo 2 is an artificial intelligence-based biological foundation model trained on 9 trillion DNA base pairs spanning all domains of life that predicts functional properties from genomic sequences and p...

lnkd.in

Arc Institute@arcinstitute.org · 6mo ago

Evo 2, the largest fully open biological AI model to date, is now published in @nature.com youtu.be/o_w-E--u7GQ

🧭 We didn’t set out to reinvent DNA synthesis. We set out to solve a problem we experienced ourselves. Want to understand the science behind Ansa’s approach, and why enzymatic synthesis changes what’s possible? Read on: ansabio.com/blog/ansas-e...

What’s possible today with large, complex DNA? This on-demand webinar walks through a real-world case: a 23 kb dystrophin plasmid synthesized in 20 business days and deployed with AI-guided delivery vehicles. 👉Watch here: hubs.li/Q03Vg1SR0 #DNASynthesis #GeneTherapy

Drug Discovery News highlights an exciting advance from New England Bio Labs and Yale University: a synthetic phage engineering platform that enables phages to be designed and built entirely in the lab. Proud that Ansa could deliver the DNA for this study. www.drugdiscoverynews.com/new-syntheti...

New synthetic phage platform could reshape antimicrobial therapy

A new system lets researchers build and reprogram phage genomes from digital sequence data, potentially enabling scalable, customizable therapies for drug-resistant bacteria.

drugdiscoverynews.com